Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-04-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第二届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 8th meeting of the 2nd Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It includes multiple agenda items such as approval of the 2018 Annual Report and its summary, the 2019 Q1 report, the 2018 Supervisory Board work report, financial budget, profit distribution plan, audit firm reappointment, internal control evaluation, accounting policy changes, asset impairment provisions, cash management proposals, fundraising project delays, related party transactions, and a regulatory corrective action report. The document contains voting results and mentions that many of these reports are published separately on the designated disclosure website. The document is not the reports themselves but a formal announcement of the Supervisory Board's resolutions regarding these reports and other corporate matters. It is a regulatory announcement of meeting resolutions rather than the full reports or financial statements. Therefore, it fits best under Regulatory Filings (RNS). The document length (5916 characters) and content support this classification rather than a full Annual Report or Interim Report.
2019-04-24 Chinese
2018年年度报告摘要
Annual Report Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 2018 年年度报告摘要" which translates to "Shenzhen BGI Genomics Co., Ltd. 2018 Annual Report Summary." It contains detailed descriptions of the company's business segments, products, and services, as well as financial data for the year 2018. The document includes audited financial statements with an unqualified opinion from Ernst & Young, references to the board of directors' approval, and detailed financial metrics. The length of the document (15,000 characters) and the presence of substantive financial data and business analysis confirm it is a full annual report rather than a brief announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2018
2019-04-24 Chinese
关于2018年年度报告及2019年第一季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (500 characters) from Shenzhen BGI Genomics Co., Ltd. It states that the 2018 Annual Report and the 2019 First Quarter Report have been disclosed on the official website. The text does not contain the actual reports or financial data but only informs investors about the availability of these reports. According to the 'MENU VS MEAL' rule, such a brief notice that points to the publication of reports is classified as a Report Publication Announcement (RPA), not the reports themselves.
2019-04-24 Chinese
关于全资子公司医疗器械注册证变更的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen BGI Genomics Co., Ltd. regarding a change in the medical device registration certificate for its wholly-owned subsidiary. It details the approval of changes to the registration certificate by the National Medical Products Administration, specifying updated applicable gene sequencing instruments. The document includes a risk warning and impact statement but does not contain financial data, earnings, or detailed report content. It is a regulatory announcement about a product registration change, not a financial report or management discussion. The document length is short (967 characters) and is an announcement of a regulatory approval rather than a report itself. Therefore, it fits best under Regulatory Filings (RNS).
2019-04-17 Chinese
关于对深圳证券交易所问询函的回复公告
Regulatory Filings Classification · 95% confidence The document is a detailed reply announcement from Shenzhen BGI Genomics Co., Ltd. to an inquiry letter from the Shenzhen Stock Exchange regarding issues related to revenue recognition, related party transactions, and internal controls. It includes explanations about R&D independence, contract details with related parties, payment schedules, and compliance with approval processes. The document is a formal regulatory response to a stock exchange inquiry, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather addresses regulatory questions and compliance matters. The document length is 3803 characters, which is relatively short and consistent with a regulatory filing or announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-04-12 Chinese
2019年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2019年第一季度业绩预告' which translates to '2019 First Quarter Earnings Forecast'. It provides estimated financial results for the period January 1, 2019 to March 31, 2019, including expected net profit and reasons for performance changes. It explicitly states that the forecast is unaudited and that detailed financial data will be disclosed in the official first quarter report. The document is short (1074 characters) and serves as an earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. Q1 2019
2019-04-09 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.